{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 43,
  "pageCount": 58,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "industry_trends",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 47,
  "notes": "The chart displays quarterly deal numbers, showing significant volatility but a clear increase in peak deal activity post-2018.",
  "elementsJson": [
    "area_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/43",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.583,
        "w": 0.926,
        "x": 0.037,
        "y": 0.217
      },
      "kind": "chart",
      "text": "China pharma and biotech license-out deals (2011 Q1-22 Q3)",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4266705-2fb2-4fa4-8291-61206f4ae71b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Quarterly deal numbers",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbf-d33d22f0d107",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.845,
        "x": 0.037,
        "y": 0.867
      },
      "kind": "source-note",
      "text": "Note: *Cortellis screening criteria: license-out deals of pharmas and biotechs with deal's principal HQ in mainland China, partner HQ outside mainland China, non-terminated deals (active, completed or pending), and agreement type of Company-JV, Company-M&A, Drug-Asset divestment, Drug-Commercialization license, Development/Drug-Commercialization license\nSource: Cortellis Deal Intelligence, L.E.K. analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8719c53c-7f40-4356-b110-c995446eef2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.042,
        "w": 0.926,
        "x": 0.037,
        "y": 0.061
      },
      "kind": "title",
      "text": "Chinese innovations are now being validated on the international stage, as their global rights are being picked up by oversea counterparts ...",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5cfd8e49-7a0d-4d03-808c-9971b4dc4c4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.018,
        "w": 0.248,
        "x": 0.037,
        "y": 0.033
      },
      "kind": "title",
      "text": "Evolution of MNC China R&D strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d30dbf70-66db-4a57-a473-ed301da0078e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}